Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. develops allosteric small molecule therapies for neurodegenerative and other difficult-to-treat diseases. The company’s lead candidate, GT-02287, is being developed for Parkinson’s disease with or without a GBA1 mutation and is designed as a brain-penetrant allosteric enzyme modulator of glucocerebrosidase, or GCase.
Recurring news for GANX includes financial results, corporate updates, clinical and biomarker data for GT-02287, FDA and IND-related communications, and scientific presentations at Parkinson’s and neurodegeneration conferences. Company updates also cover the Magellan™ drug discovery platform, preclinical GCase modulator programs such as GT-04686, and pipeline areas including lysosomal storage disorders, metabolic diseases and solid tumors.
Gain Therapeutics (Nasdaq: GANX) reported Q2 2026 results and a corporate update, highlighted by FDA acceptance of its IND for lead Parkinson’s candidate rexaceract (GT-02287), enabling planned initiation of a Phase 2 trial in the U.S. in Q3 2026.
Phase 1b interim extension data in 16 Parkinson’s patients showed stable MDS‑UPDRS scores through at least Day 150, with greater benefit in those with high baseline CSF GluSph and continued non‑progression signals through Days 270 and 360. Second asset GT‑04686 is progressing toward IND‑enabling studies, with initial indication selection expected by year end.
Q2 2026 R&D expenses were $2.1 million versus $2.8 million a year earlier, while G&A expenses rose to $2.5 million from $2.3 million. Net loss was $4.7 million, or $0.11 per share, compared with $5.8 million, or $0.19 per share, in Q2 2025. Cash and cash equivalents totaled $13.1 million as of June 30, 2026.
Gain Therapeutics (Nasdaq: GANX) CEO Gene Mack issued a shareholder letter outlining clinical, pipeline, organizational and financial updates. The company’s lead Parkinson’s disease candidate rexaceract completed 150 days of dosing in a Phase 1b open-label extension, with all 16 participants remaining on study and an independent Data Monitoring Committee recommending continuation without modification. Earlier 90-day data showed an average 81% reduction in cerebrospinal fluid GluSph among participants with elevated baseline levels, alongside decreased DOPA decarboxylase and stabilized or improved MDS-UPDRS scores, including a 4.8-point difference favoring those with high baseline GluSph. The FDA has authorized an IND, and a Phase 2 trial in early Parkinson’s is expected to begin in 3Q26. Gain is also advancing second GCase modulator GT-04686 toward IND-enabling studies and promoted Joanne Taylor to Chief Scientific Officer and Terenzio Ignoni to Chief Operating Officer. As of March 31, 2026, cash and equivalents were $16.5 million, which the company expects will fund operations into 2Q27, including completion of the Phase 1b extension and initiation of Phase 2.
Gain Therapeutics (Nasdaq: GANX) received FDA clearance of its IND for GT-02287, allowing Phase 2 development in Parkinson’s disease with or without GBA1 mutation in the U.S. Phase 2a initiation is expected in 3Q26 across the U.S., Australia, and Europe.
Phase 1b extension data showed sustained target engagement, including an average 81% CSF GluSph reduction at 90 days in participants with elevated baseline levels, favorable safety and tolerability through five months, and stable or improved motor scores.
Gain Therapeutics (Nasdaq: GANX) announced that President and CEO Gene Mack will join a virtual fireside chat and one-on-one meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, held June 15-16, 2026.
The fireside chat replay starts June 15, 2026, at 7:00 a.m. EDT and will be accessible via the event link or the company’s “Investors & Media/News & Events” webpage. Registered attendees can request one-on-one meetings with Gain management through H.C. Wainwright, while others may email ir@gaintherapeutics.com to arrange discussions.
Gain Therapeutics (Nasdaq: GANX) reported positive interim data from its Phase 1b study of GT-02287 in idiopathic and GBA1 Parkinson’s disease, presented at the 3rd International GBA1 Meeting 2026.
All 16 extension participants completed 150 days of dosing with stable MDS-UPDRS scores overall and a 4.8-point Part II+III difference favoring patients with high baseline CSF GluSph. According to Gain Therapeutics, CSF GluSph fell 81% after 90 days in patients with elevated baseline levels, with accompanying DDC decreases. Participants also commonly reported perceived improvements in smell and taste, balance or gait, and sleep. A Data Monitoring Committee recommended the study continue unchanged, and a Phase 2 trial is planned with objective smell and gait endpoints.
Gain Therapeutics (Nasdaq: GANX) reported Q1 2026 results and a corporate update centered on Parkinson’s candidate GT-02287 and GCase modulator GT-04686.
Q1 R&D was $2.8M, G&A $2.6M, net loss was $0.13 per share, and cash and securities totaled $16.5M.
Gain Therapeutics (NASDAQ: GANX) will deliver an oral presentation at the 3rd International GBA1 Meeting 2026 on May 22, 2026 in Phoenix, AZ. The talk is titled “An update on the development of the GCase modulator GT-02287 for Parkinson’s disease”.
Jonas Hannestad, M.D., Ph.D., Chief Medical Officer, is listed as the presenter for a 15-minute session on May 22 at 4:15–4:30pm MST. Management will also attend the 7th World Parkinson’s Congress, May 24–27, 2026 in Phoenix.
Gain Therapeutics (Nasdaq: GANX) reported 2025 year-end results and a clinical update for lead candidate GT-02287. Key metrics: net loss $20.2M (2025), cash and marketable securities $20.8M at 12/31/25, R&D $10.2M, G&A $8.5M. Clinical highlights include Phase 1b extension enrollment of 16 participants (14 completed Day 150), an average 81% decrease in CSF GluSph after 90 days in participants with elevated baseline, and IND interaction with FDA with IND clearance expected in 2Q26. Phase 2 is expected to begin in 3Q26 and Phase 1b results are expected in 4Q26.
Gain Therapeutics (NASDAQ: GANX) announced that Gene Mack, President and CEO, will participate in a fireside chat and one-on-one meetings at the 38th Annual ROTH Conference in Dana Point, CA, March 22-24, 2026. The fireside chat is scheduled for March 23, 2026 at 11:30 a.m. PT.
Investors can access a live webcast or replay via the company website or contact ir@gaintherapeutics.com to arrange meetings through ROTH representatives.
Gain Therapeutics (NASDAQ: GANX) presented Phase 1b clinical and preclinical data at AD/PD 2026 supporting continued development of GT-02287 and a new chemical series led by GT-04686.
Key clinical signals include reductions in CSF glucosylsphingosine (GluSph) after 90 days, decreased CSF DOPA decarboxylase (DDC) in high‑GluSph participants, and durable MDS‑UPDRS scores through Day 150. The novel series is ready for IND‑enabling studies; the Part 1 safety profile supported a nine‑month extension expected to complete in September 2026.